Prognostic heterogeneity of adult B‐cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3‐PBX1 treated with measurable residual disease‐oriented protocols

The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the o...

Descripción completa

Detalles Bibliográficos
Autores: Ribera, Jordi, Granada, Isabel, Morgades, Mireia, González, Teresa, Ciudad, Juana, Such, Esperanza, Calasanz, María José, Mercadal, Santiago, Coll, Rosa, González Campos, José, Tormo, Mar, García Cadenas, Irene, Gil, Cristina, Cervera, Marta, Barba, Pere, Costa, Dolors, Ayala, Rosa, Bermúdez, Arancha, Orfao, Alberto, Ribera, Josep Maria, Programa Español de Tratamiento en Hematología (PETHEMA) Group Spanish Society Of Hematology (SEHH)
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/180373
Acceso en línea:https://hdl.handle.net/2445/180373
Access Level:acceso abierto
Palabra clave:Pronòstic mèdic
Leucèmia
Citogenètica humana
Prognosis
Leukemia
Human cytogenetics
Descripción
Sumario:The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).

Similares en LA Referencia